Related references
Note: Only part of the references are listed.Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis
Sheila Bohler et al.
HAEMATOLOGICA (2021)
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Rachel Thijssen et al.
BLOOD (2021)
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study
Daniel A. Pollyea et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
Benshang Li et al.
BLOOD (2020)
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis
Sha Jin et al.
CLINICAL CANCER RESEARCH (2020)
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Donia M. Moujalled et al.
BLOOD ADVANCES (2020)
Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia-From Single Cell Analysis to Next-Generation Sequencing
Anna Deregowska et al.
GENES (2020)
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt et al.
CANCER CELL (2020)
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al.
LEUKEMIA (2019)
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Ernesto Diaz-Flores et al.
CANCER RESEARCH (2019)
Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia
Klaudyna Fidyt et al.
MOLECULAR ONCOLOGY (2019)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Felix Seyfried et al.
CELL DEATH & DISEASE (2019)
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
Jeffrey Wang et al.
BLOOD CANCER JOURNAL (2019)
Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL plus acute lymphoblastic leukemia
Michaela Scherr et al.
LEUKEMIA (2019)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation
Filip Radenkovic et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Viktoras Frismantas et al.
BLOOD (2017)
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Seong Lin Khaw et al.
BLOOD (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia
D. Pal et al.
LEUKEMIA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia
Stefania Trino et al.
FRONTIERS IN PHARMACOLOGY (2016)
Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway
Jessica T. Leonard et al.
BLOOD (2016)
Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response
Felix Seyfried et al.
BLOOD (2016)
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Sarah E. Alford et al.
CANCER RESEARCH (2015)
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Christopher J. Gibson et al.
CLINICAL CANCER RESEARCH (2015)
Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
Jennifer Richmond et al.
CLINICAL CANCER RESEARCH (2015)
An interconnected hierarchical model of cell death regulation by the BCL-2 family
Hui-Chen Chen et al.
NATURE CELL BIOLOGY (2015)
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Ute Fischer et al.
NATURE GENETICS (2015)
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Juliana M. Benito et al.
CELL REPORTS (2015)
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis
Anna Stengel et al.
BLOOD (2014)
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth
Ningning Liu et al.
ONCOTARGET (2014)
Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction
Patricia Gomez-Bougie et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes
Debabrata Biswas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent Transcription
Akihiko Yokoyama et al.
CANCER CELL (2010)
AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Subunit of MLL Chimeras, Can Link Transcription Elongation to Leukemia
Chengqi Lin et al.
MOLECULAR CELL (2010)
The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation
Andrew G. Cox et al.
BIOCHEMICAL PHARMACOLOGY (2008)
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Dorothee Mueller et al.
BLOOD (2007)
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
Mikhail A. Nikiforov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Ubiquitination and degradation of mutant p53
Natalia Lukashchuk et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Structural insights into the degradation of Mcl-1 induced by BH3 domains
Peter E. Czabotar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications
TA Milne et al.
CANCER RESEARCH (2005)
Life in the balance: how BH3-only proteins induce apoptosis
SN Willis et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin
DT Zeisig et al.
ONCOGENE (2005)
Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase
MP Rigobello et al.
FREE RADICAL RESEARCH (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia
X Agirre et al.
MOLECULAR CARCINOGENESIS (2003)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
Share Paper
